Healthcare provider profile · identity verified

David De La Pena, D.O.

Internal Medicine · KETTERING, OH · NPI 1477085702

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	596	180
Levothyroxine Sodium	Levothyroxine Sodium	347	99
Gabapentin	Gabapentin	318	111
Amlodipine Besylate	Amlodipine Besylate	304	92
Losartan Potassium	Losartan Potassium	255	79
Lisinopril	Lisinopril	240	76
Rosuvastatin Calcium	Rosuvastatin Calcium	240	72
Metformin Hcl	Metformin Hcl	213	62
Omeprazole	Omeprazole	190	61
Tamsulosin Hcl	Tamsulosin Hcl	187	61
Duloxetine Hcl	Duloxetine Hcl	160	44
Metoprolol Succinate	Metoprolol Succinate	147	48
Pantoprazole Sodium	Pantoprazole Sodium	125	44
Allopurinol	Allopurinol	115	38
Furosemide	Furosemide	106	38
Finasteride	Finasteride	105	29
Carvedilol	Carvedilol	98	31
Metoprolol Tartrate	Metoprolol Tartrate	97	31
Tizanidine Hcl	Tizanidine Hcl	95	40
Hydrochlorothiazide	Hydrochlorothiazide	92	30
Metformin Hcl Er	Metformin Hcl	91	32
Simvastatin	Simvastatin	89	26
Tramadol Hcl	Tramadol Hcl	89	27
Trazodone Hcl	Trazodone Hcl	87	33
Pravastatin Sodium	Pravastatin Sodium	85	27
Albuterol Sulfate Hfa	Albuterol Sulfate	84	31
Eliquis	Apixaban	80	24
Montelukast Sodium	Montelukast Sodium	78	33
Glimepiride	Glimepiride	75	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	70	22
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	66	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	62	18
Citalopram Hbr	Citalopram Hydrobromide	60	14
Fluticasone Propionate	Fluticasone Propionate	60	28
Potassium Chloride	Potassium Chloride	59	25
Prednisone	Prednisone	58	38
Sertraline Hcl	Sertraline Hcl	58	22
Clopidogrel	Clopidogrel Bisulfate	57	21
Famotidine	Famotidine	56	22
Meloxicam	Meloxicam	55	21
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	52	suppressed
Methocarbamol	Methocarbamol	50	26
Donepezil Hcl	Donepezil Hcl	49	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	48	13
Jardiance	Empagliflozin	45	14
Tresiba Flextouch U-100	Insulin Degludec	43	suppressed
Ezetimibe	Ezetimibe	41	12
Spironolactone	Spironolactone	41	17
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	40	32
Lorazepam	Lorazepam	40	13
Azithromycin	Azithromycin	39	35
Fluoxetine Hcl	Fluoxetine Hcl	39	15
Synthroid	Levothyroxine Sodium	35	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	34	14
Glipizide Er	Glipizide	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Memantine Hcl	Memantine Hcl	32	suppressed
Bupropion Xl	Bupropion Hcl	31	14
Pioglitazone Hcl	Pioglitazone Hcl	31	11
Alprazolam	Alprazolam	30	suppressed
Glipizide	Glipizide	30	suppressed
Ozempic	Semaglutide	30	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	29	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	29	12
Atenolol	Atenolol	28	suppressed
Mirtazapine	Mirtazapine	28	suppressed
Nifedipine Er	Nifedipine	28	suppressed
Clonazepam	Clonazepam	27	suppressed
Fenofibrate	Fenofibrate	27	suppressed
Buspirone Hcl	Buspirone Hcl	26	12
Olmesartan Medoxomil	Olmesartan Medoxomil	26	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	24	11
Mounjaro	Tirzepatide	24	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	24	suppressed
Meclizine Hcl	Meclizine Hcl	23	15
Bumetanide	Bumetanide	22	suppressed
Januvia	Sitagliptin Phosphate	22	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	17
Trulicity	Dulaglutide	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	14
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	15
Estradiol	Estradiol	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	12
Terazosin Hcl	Terazosin Hcl	18	suppressed
Valsartan	Valsartan	18	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	15
Insulin Lispro Kwikpen U-100	Insulin Lispro	17	suppressed
Alendronate Sodium	Alendronate Sodium	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Telmisartan	Telmisartan	16	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Levofloxacin	Levofloxacin	15	12
Single Use Swab	Alcohol Antiseptic Pads	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Cholestyramine	Cholestyramine (With Sugar)	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Klor-Con M20	Potassium Chloride	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Spiriva Handihaler	Tiotropium Bromide	13	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Dexamethasone	Dexamethasone	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Minocycline Hcl	Minocycline Hcl	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Torsemide	Torsemide	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Lovastatin	Lovastatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error